MAIN MENU
QUICK LINKS
CONNECT WITH US

Button

Pulmonary, Critical Care and Sleep Medicine: Clinical Research

A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’(SSc-ILD).

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment

An Open-Label Extension Study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension Due to Parenchymal Lung Disease

An open-label extension trial to assess the long term safety of nintedanib in patients with "Systemic Sclerosis associated Interstitial Lung Disease" (SSC-ILD)
Keywords: Systemic Sclerosis;

BIPI Protocols 1199.247: A Double-blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52-weeks in Patients with Progressive Fibrosing Interstital Lung Disease (PF-ILD)

For TDE-PH-310: A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy An Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial Hypertension - A Long-Term Follow-Up to Protocol TDE-PH-310

OPUS Registry Opsumit® (macitentan) Users Registry

Uptravi® (SelexiPag): tHe usErs dRug rEgistry (SPHERE) Registry Uptravi® (Selexipag) Users Registry PROTOCOL: AC-065A402

1